Methyl 3-iodo-4-methylbenzoate, 98%
Methyl 3-iodo-4-methylbenzoate, 98%
Methyl 3-iodo-4-methylbenzoate, 98%
Methyl 3-iodo-4-methylbenzoate, 98%
Thermo Scientific Chemicals

Methyl 3-iodo-4-methylbenzoate, 98%

CAS: 90347-66-3 | C9H9IO2 | 276.073 g/mol
製品番号(カタログ番号) H28734.14
または、製品番号H28734-14
価格(JPY)
-
見積もりを依頼する
数量:
25 g
一括またはカスタム形式をリクエストする
化学物質識別子
CAS90347-66-3
IUPAC Namemethyl 3-iodo-4-methylbenzoate
Molecular FormulaC9H9IO2
InChI KeyNKMHAOTZPFVSPC-UHFFFAOYSA-N
SMILESCOC(=O)C1=CC(I)=C(C)C=C1
さらに表示
Appearance (Color)Clear colorless to yellow
Assay (GC)≥97.5%
Refractive Index1.5955-1.5995 @ 20?C
FormLiquid
Methyl 3-Iodo-4-methylbenzoate is used as a reagent in the synthesis of [(pyrazolo[1,5-a]pyridmidinyl)ethynyl]benzamides as selective discoidin domain receptor 1 (DDR1) inhibitors. Also used as a reagent in the preparation of orally bioavailable GZD824 targeting Breakpoint Cluster Region-Abelson (Bcr-Abl) kinase and overcoming antitumor drug resistance.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Applications
Methyl 3-Iodo-4-methylbenzoate is used as a reagent in the synthesis of [(pyrazolo[1,5-a]pyridmidinyl)ethynyl]benzamides as selective discoidin domain receptor 1 (DDR1) inhibitors. Also used as a reagent in the preparation of orally bioavailable GZD824 targeting Breakpoint Cluster Region-Abelson (Bcr-Abl) kinase and overcoming antitumor drug resistance.

Solubility
Not miscible or difficult to mix with water.

Notes
Light Sensitive, store in dark. Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Store away from oxidizing agent.
RUO – Research Use Only

General References:

  1. Gao, M., et al. Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors. J. Med. Chem. 2013, 56(8), 3281-3295.
  2. Ren, X., et al. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib.J. Med. Chem. 2013, 56(3), 879-894.